atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug
- Posted on: 2022-11-10
- |
- Views: 320
Oct. 12, 2022
By: Jonathan Block
A drug from atai Life Sciences (NASDAQ:ATAI) based on an active component found in the plant kratom led to pain-relieving effects in an early-stage trial.
The candidate, KUR-101, is an oral form of deuterated mitragynine, the major active alkaloid found in kratom. It is under investigation for opioid use disorder.
Results showed that KUR-101 was safe and well-tolerated with a dose-proportional pharmacokinetic profile.
Additional results, including comparing a single dose of KUR-101 to a single dose of oxycodone or placebo, is expected by the end of the year.